Diagnostics and therapy of hepatorenal syndrome.
Recommendations of of the working group on portal hypertension of the Czech Hepatology Society and the J. E. Purkinje Czech Medical Society.
Authors:
R. Brůha (koordinátor) 1; Členové Skupiny: P. Drastich 2; P. Hůlek 3; J. Lata 4; J. Petrtýl 1; V. Procházka 5
; J. Špičák 2; T. Vaňásek 3; M. Volfová 3; P. Zdeněk 6
Authors‘ workplace:
IV. interní klinika 1. lékařské fakulty UK a VFN, Praha, přednosta doc. MUDr. Aleš Žák, DrSc.
1; Klinika hepatogastroenterologie IKEM, Praha, přednosta doc. MUDr. Julius Špičák, CSc.
2; II. interní klinika Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc.
3; Interní gastroenterologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Petr Dítě, DrSc.
4; II. interní klinika Lékařské fakulty UP a FN Olomouc, přednosta doc. MUDr. Vlastimil Procházka, Ph. D.
5; I. interní klinika Lékařské fakulty UK a FN Plzeň, přednosta †prof. MUDr. Karel Opatrný, jr, DrSc.
6
Published in:
Vnitř Lék 2006; 52(6): 649-650
Category:
Guidelines
Doporučený postup pro léčbu hepatorenálního syndromu byl schválen výborem České hepatologické společnosti České lékařské společnosti J. E. Purkyně v prosinci roku 2005.
Overview
Hepatorenal syndrome is a functional renal failure in patients with advanced cirrhosis and portal hypertension or acute liver failure. It is caused by extreme vasoconstriction in renal arterial bed. Type I HRS presents as an acute renal failure, while type II HRS is chronic alteration of renal function in patients with refractory ascites. Prognosis of HRS is very poor with survival reaching several weeks in patients with HRS type I. Causal treatment is liver transplantation, other treatment options include use of splanchnic vasoconstrictors (terlipressin) together with plasmaexpansion (albumin) and TIPS. It is important to exclude nephrotoxic medication (non-steroid anti inflammatory drugs, aminoglycosides) and properly treat all infective complications in prevention of HRS.
Key words:
cirrhosis - hepatorenal syndrome - portal hypertension
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2006 Issue 6
-
All articles in this issue
- Comparison of plasmatic levels of B-natriuretic peptide with echocardiographic indicators of left ventricle function after doxorubicin therapy
- Obesity and progression of chronic renal insufficiency: a Czech long term prospective double-blind randomised multicentre study
- Molecular genetic diagnostics and screening of hereditary hemochromatosis
- Nuclear receptors PPARα
- Biological treatment of rheumatic diseases
- Chronic renal disease and gravidity – case study
- Post-transplantation lymphoproliferation in patients with intensive immunosuppression
-
Diagnostics and therapy of hepatorenal syndrome.
Recommendations of of the working group on portal hypertension of the Czech Hepatology Society and the J. E. Purkinje Czech Medical Society. - Sustained monomorphic ventricular tachycardia in patients with structural heart disease. Different arrhythmogenic substrates, different options of palliative and curative treatment in the era of three-dimensional mapping
- Prevalence and causes of reflux in deep venous system of the leg in patients with insufficiency of superficial veins
- Trimetazidine in the treatment of stable angina pectoris TRIADA – (TRImetazidine in stable Angina twice Daily)
- Impact of endocannabinoid system in modulation of the metabolic syndrome
-
Ubiquitins, proteasomes, sumoylation and application today and in future for cancer and other diseases therapy II.
Sumoylation and neddylation as posttranslational modifications of proteins and their significance
- Internal Medicine
- Journal archive
- Current issue
- Online only
- About the journal
Most read in this issue
- Nuclear receptors PPARα
- Prevalence and causes of reflux in deep venous system of the leg in patients with insufficiency of superficial veins
- Sustained monomorphic ventricular tachycardia in patients with structural heart disease. Different arrhythmogenic substrates, different options of palliative and curative treatment in the era of three-dimensional mapping
- Molecular genetic diagnostics and screening of hereditary hemochromatosis